[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
作者信息
Dalmases Alba, Rojo Federico, Rovira Ana, Albanell Joan
机构信息
Departamento de Oncología Médica, Hospital del Mar, Barcelona, España.
出版信息
Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27.
PMID:23809407
Abstract
摘要
相似文献
1
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].[肿瘤学中靶向治疗的应用及其对临床试验设计的影响：以表皮生长因子受体1和2为例]
Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27.
2
Update on HER-kinase-directed therapy in prostate cancer.前列腺癌中HER激酶导向治疗的最新进展。
Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64.
3
Ten years of HER2-directed therapy: still questions after all these years.十年的HER2靶向治疗：多年之后仍有诸多问题。
Breast Cancer Res Treat. 2009 Jan;113(2):207-9. doi: 10.1007/s10549-008-0041-2. Epub 2008 May 8.
4
[Breast cancer and Her-2].[乳腺癌与人类表皮生长因子受体2]
Nihon Rinsho. 2007 Jun 28;65 Suppl 6:87-94.
5
Anti-epidermal growth factor receptor strategies for advanced breast cancer.晚期乳腺癌的抗表皮生长因子受体策略
Cancer Invest. 2008 Oct;26(8):757-68. doi: 10.1080/07357900801971040.
6
[The potential of monoclonal antibodies in cancer : established trastuzumab and cetuximab and promising targets IGF-1R and c-MET].[单克隆抗体在癌症治疗中的潜力：已确立的曲妥珠单抗和西妥昔单抗以及有前景的靶点IGF-1R和c-MET]
Med Sci (Paris). 2009 Dec;25(12):1090-8. doi: 10.1051/medsci/200925121090.
7
ErbB/HER receptor family in breast cancer--the more we search the more we learn.乳腺癌中的表皮生长因子受体（ErbB/HER）家族——我们探索得越多，了解得就越多。
Ann Oncol. 2008 May;19(5):1020-1. doi: 10.1093/annonc/mdn061. Epub 2008 Mar 19.
8
Dual blockade of HER2 - twice as good or twice as toxic?曲妥珠单抗联合帕妥珠单抗治疗 HER2 阳性乳腺癌：是疗效加倍还是毒性加倍？
Clin Oncol (R Coll Radiol). 2012 Nov;24(9):593-603. doi: 10.1016/j.clon.2012.05.009. Epub 2012 Jun 28.
9
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.曲妥珠单抗和拉帕替尼耐药的 HER2 阳性乳腺癌细胞丧失对 HER2 的依赖，并对多靶点激酶抑制剂索拉非尼敏感。
Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.
10
[Her2 a paradigm for targeted therapy].[人表皮生长因子受体2：靶向治疗的范例]
Bull Cancer. 2011 Oct;98(9):1011-7. doi: 10.1684/bdc.2011.1379.
Zotero 插件